1. Home
  2. CRF vs MNKD Comparison

CRF vs MNKD Comparison

Compare CRF & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

N/A

Current Price

$6.10

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo MannKind Corporation

MNKD

MannKind Corporation

N/A

Current Price

$3.57

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRF
MNKD
Founded
N/A
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
1997
2004

Fundamental Metrics

Financial Performance
Metric
CRF
MNKD
Price
$6.10
$3.57
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$8.69
AVG Volume (30 Days)
1.6M
3.0M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
N/A
$35.81
Revenue Next Year
N/A
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.23
52 Week Low
$6.30
$2.23
52 Week High
$8.25
$6.51

Technical Indicators

Market Signals
Indicator
CRF
MNKD
Relative Strength Index (RSI) 26.31 35.94
Support Level N/A $3.30
Resistance Level $7.31 $4.23
Average True Range (ATR) 0.08 0.16
MACD -0.00 -0.05
Stochastic Oscillator 21.28 3.03

Price Performance

Historical Comparison
CRF
MNKD

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: